Gale Scott on Muck Rack

Gale Scott

Verified
Cranbury
As seen in: Health Payer Specialist, Financial Times, Phys.org, Crain's New York Business, HCP Live, The Franklin News-Post, Health System Specialist

Get in touch with Gale

Contact Gale, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Gale Scott’s Biography

Read Full Bio →

Gale Scott is Deputy Executive Editor of MD Magazine. She covers medical conferences and writes about news and issues on a variety of topics, with a special focus on cardiology and neurology.

Articles

Princeton researchers working at forefront of 'exascale' supercomputing

|
By Gale Scott 
| Phys.org
The capacity to deploy computations at such an extreme scale could put scientists closer to solving a wide range of research problems, including the quest to make fusion energy a safe, affordable power source, according to William Tang, head of the Fusion Simulation Program at the U.S. Department of Energy's Princeton Plasma Physics Laboratory (PPPL). The new computing power would also greatly enhance the realism of simulations used in that research.
Open in Who Shared Issue with article?

FDA Approves Drug for Rare Muscle Disorder

|
By Gale Scott 
| mdmag.com
The US Food and Drug Administration (FDA) today approved deflazacort (Emflaza/Marathon Pharmaceuticals) an orphan drug used to treat patients five years and older for Duchenne muscular dystrophy (DMD). The ailment is a rare genetic disorder that causes progressive muscle deterioration and weakness. Emflaza is a corticosteroid that works by decreasing inflammation and reducing the activity of the immune system. Corticosteroids are commonly used to treat DMD across the world.
Open in Who Shared Issue with article?

Chronic Kidney Disease Drug Approved

|
By Gale Scott 
| mdmag.com
The US Food and Drug Administration today approved etelcalcetide (Parsabiv/Amgen) for treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease who are on dialysis.The drug is an intravenous cacimimetic.According to Amgen's Sean Harper, MD, executive vice president of Research and Development, "Parsabiv not only has demonstrated strong efficacy in clinical trials, it fills an unmet need by putting the delivery of the therapy in the hands of the health care...
Open in Who Shared Issue with article?
See all 8 licensed articles (35 Total)

Actions

Share this page

Get in touch with Gale

Contact Gale, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified